257 related articles for article (PubMed ID: 15658501)
1. [Pharmacology of second-generation antipsychotics: a validity of the serotonin-dopamine hypothesis].
Kuroki T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Oct; 24(5):257-64. PubMed ID: 15658501
[TBL] [Abstract][Full Text] [Related]
2. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
Kuroki T; Nagao N; Nakahara T
Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
[TBL] [Abstract][Full Text] [Related]
3. Serotonin receptors: their key role in drugs to treat schizophrenia.
Meltzer HY; Li Z; Kaneda Y; Ichikawa J
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
[TBL] [Abstract][Full Text] [Related]
4. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes.
Moran-Gates T; Massari C; Graulich A; Liégeois JF; Tarazi FI
J Neurosci Res; 2006 Aug; 84(3):675-82. PubMed ID: 16810690
[TBL] [Abstract][Full Text] [Related]
6. Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action.
Hertel P
Synapse; 2006 Dec; 60(7):543-52. PubMed ID: 16952163
[TBL] [Abstract][Full Text] [Related]
7. Role of serotonin in the action of atypical antipsychotic drugs.
Meltzer HY
Clin Neurosci; 1995; 3(2):64-75. PubMed ID: 7583621
[TBL] [Abstract][Full Text] [Related]
8. [Critical review of mechanisms of action of second-generation antipsychotic drugs].
Miyamoto S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2006 Nov; 26(5-6):199-208. PubMed ID: 17240845
[TBL] [Abstract][Full Text] [Related]
9. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
Assié MB; Ravailhe V; Faucillon V; Newman-Tancredi A
J Pharmacol Exp Ther; 2005 Oct; 315(1):265-72. PubMed ID: 15987834
[TBL] [Abstract][Full Text] [Related]
10. The role of serotonin receptors in the action of atypical antipsychotic drugs.
Meltzer HY; Massey BW
Curr Opin Pharmacol; 2011 Feb; 11(1):59-67. PubMed ID: 21420906
[TBL] [Abstract][Full Text] [Related]
11. The role of serotonin in antipsychotic drug action.
Meltzer HY
Neuropsychopharmacology; 1999 Aug; 21(2 Suppl):106S-115S. PubMed ID: 10432496
[TBL] [Abstract][Full Text] [Related]
12. Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone.
Ohno Y; Ishida-Tokuda K; Ishibashi T; Sakamoto H; Tagashira R; Horisawa T; Yabuuti K; Matsumoto K; Kawabe A; Nakamura M
Pol J Pharmacol; 1997 Aug; 49(4):213-9. PubMed ID: 9437764
[TBL] [Abstract][Full Text] [Related]
13. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
[TBL] [Abstract][Full Text] [Related]
14. Antimanic potency of typical neuroleptic drugs and affinity for dopamine D2 and serotonin 5-HT2A receptors--a new analysis of data from the archives and implications for improved antimanic treatments.
Harrison-Read PE
J Psychopharmacol; 2009 Nov; 23(8):899-907. PubMed ID: 18635692
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R
Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418
[TBL] [Abstract][Full Text] [Related]
16. Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action.
Di Pietro NC; Seamans JK
Pharmacopsychiatry; 2007 Dec; 40 Suppl 1():S27-33. PubMed ID: 18080940
[TBL] [Abstract][Full Text] [Related]
17. Behavioural pharmacology of the new generation of antipsychotic agents.
Moore NA
Br J Psychiatry Suppl; 1999; (38):5-11. PubMed ID: 10884895
[TBL] [Abstract][Full Text] [Related]
18. Messing up with traffic: different effects of antipsychotic agents on glutamate receptor complexes in vivo.
Del'guidice T; Beaulieu JM
Mol Pharmacol; 2008 May; 73(5):1339-42. PubMed ID: 18314495
[TBL] [Abstract][Full Text] [Related]
19. The importance of serotonin-dopamine interactions in the action of clozapine.
Meltzer HY
Br J Psychiatry Suppl; 1992 May; (17):22-9. PubMed ID: 1358125
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
